Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a ...

Ipsen delivered strong performance in the third quarter of 2026, with total sales growth of 24.6% at constant exchange rates, driven by continued momentum across Oncology, Rare Disease and ...

We are living in an era of extraordinary scientific progress. We can target diseases in ways that were unimaginable a generation ago, develop increasingly sophisticated medicines and explore entirely ...

As the Ipsen team departs for #ESMO2026 in Madrid, one area I am particularly interested in is the growing role of real-world data in helping us understand cancer care beyond the clinical trial ...

Illness is something that touches all of us, directly or indirectly. Our parents, our children, our friends, our grandparents, no one is untouched. For Inès Quinty, this reality became deeply personal ...

“Our outstanding performance in the first nine months of 2026 is driven by the strength of our core portfolio and continued growth of Somatuline. This momentum, combined with disciplined execution, ...

Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 ...

Marc de Garidel – Chairman of the Board of Directors Marc de Garidel joined Ipsen as Chairman and Chief Executive Officer in November 2010. He has been the Ipsen Chairman of the Board of Directors ...

PARIS, France, 18 December 2019 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced that David Meek has resigned as the company’s Chief Executive Officer and will step down from the Board of Directors ...

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia. Detailed Description: This is a Phase 3, multi-center, open-label ...

This was an exploratory proof of concept study to determine the clinical activity of tasquinimod in patients with advanced or metastatic hepatocellular carcinoma, ovarian carcinoma, renal cell ...